Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus

Thomas A. Zelniker,Stephen D. Wiviott,Itamar Raz,KyungAh Im,Erica L. Goodrich,Remo Holanda de Mendonça Furtado,Marc P. Bonaca,Ofri Mosenzon,Eri Toda Kato,Avivit Cahn,Deepak L. Bhatt,Lawrence A. Leiter,Darren K. McGuire,John Wilding,Marc S. Sabatine

Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus

2019

Thomas A. Zelniker
Stephen D. Wiviott
Itamar Raz
KyungAh Im
Erica L. Goodrich
Remo Holanda de Mendonça Furtado
Marc P. Bonaca
Ofri Mosenzon
Eri Toda Kato
Avivit Cahn
Deepak L. Bhatt
Lawrence A. Leiter
Darren K. McGuire
John Wilding
Marc S. Sabatine

Background: Glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) have emerged as 2 new classes of antihyperglycemic agents that also reduce car...

Keywords:

Pharmacology
Diabetes mellitus
Type 2 Diabetes Mellitus
Peptide
Internal medicine
Medicine
Glucagon
Cardiology
Antihyperglycemic Agents
Sodium/Glucose Cotransporter 2
Receptor

Correction
Cite
Save
Machine Reading By IdeaReader

References

Citations